Name: CGRP 8-37 (human)
Brand: GlpBio
SKU: GC16147
Availability: InStock
Rating: 5 (4 reviews)

GlpBio Products Cited In Reputable Papers

Nature
610.7931 (2022): 366-372

Nature
618, 1017–1023 (2023)

Cell
183.7 (2020): 1867-1883

Cell Research
31, 1291–1307 (2021)

Cell Research
33, 273–287 (2023)

Cell Research
33, 546–561 (2023)

Molecular Cancer
21.1 (2022): 1-17

Molecular Cancer
21.1 (2022): 1-18

Cancer Cell
39 (2021): 1-16

Cell Host Microbe
30.8 (2022): 1124-1138

Cell Host Microbe
31.5 (2023): 766-780

Cell Host Microbe
31.3 (2023): 418-43

Cell Metabolism
34.2 (2022): 240-255

Ann Rheum Dis
82(4): 533-545 (2023)

Cell Mol Immunol
20, 264–276 (2023)

Adv Funct Mater
33.35 (2023): 2214998

Product Documents

Quality Control & SDS

View current batch:

Purity: >98.00%

Protocol

Cell experiment [1]:
Cell lines	Rat VSMCs
Preparation Method	Cells were pre-treated with or without test compounds for the indicated time periods and then stimulated with or without Ang II for 30 minutes and CGRP for 60 minutes. In some experiments, CGRP 8-37 (human) or H-89 was added 30 minutes, dibutyl-cAMP 60 minutes and apocynin 2 hours before CGRP treatment.
Reaction Conditions	CGRP 8-37 (human) (3 × 10-5 mol/L) for 30 minute
Applications	Pre-treatment with H-89 or CGRP 8-37 (human) also blocked the CGRP inhibitory effects against Ang II-induced oxidative stress.
Animal experiment [2]:
Animal models	Male Sprague±Dawley rats (175±200 g)
Preparation Method	Rts were given a spinal hemisection or a sham surgery at the T13 spinal segment. An externally accessible PE-10 intrathecal catheter that terminated at T13 was used for drug delivery. CGRP 8-37 (human) was delivered just prior to a testing session in 1, 5, 10, or 50 nM doses in artificial cerebral spinal fluid in 10 microl volumes.
Dosage form	CGRP 8-37 (human)as1,5, 10, or 50 nM doses in artificial cerebral spinal fluid in 10 microl volume.
Applications	CGRP 8-37 (human) is effective in abolishing mechanical and thermal allodynia produced by spinal hemisection.
References: [1]. Luo HM, Wu X, et,al. Calcitonin gene-related peptide inhibits angiotensin II-induced NADPH oxidase-dependent ROS via the Src/STAT3 signalling pathway. J Cell Mol Med. 2020 Jun;24(11):6426-6437. doi: 10.1111/jcmm.15288. Epub 2020 May 5. PMID: 32372557; PMCID: PMC7294141. [2]. Bennett AD, Chastain KM, et,al. Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain. Pain. 2000 May;86(1-2):163-75. doi: 10.1016/s0304-3959(00)00242-6. PMID: 10779673.

CGRP 8-37 (human)is a highly selective CGRP receptor antagonists.

CGRP significantly suppressed the level of reactive oxygen species (ROS) generated by NADPH oxidase in Ang II-induced VSMCs. The Ang II-stimulated activation of both Src and the downstream transcription factor, STAT3, was abrogated by CGRP. However, the antioxidative effect of CGRP was lost following the expression of constitutively activated Src or STAT3. Pre-treatment with H-89 or CGRP 8-37 (human) also blocked the CGRP inhibitory effects against Ang II-induced oxidative stress^[1].

CGRP 8-37 (human) is effective in abolishing mechanical and thermal allodynia produced by spinal hemisection^[2].When explored the effects of calcitonin gene-related peptide (CGRP) and its antagonist CGRP 8-37 (human) on the latency to hindpaw withdrawal responses induced by both thermal and mechanical stimulation in rats. CGRP 8-37 (human) (5nM or 10nM) induced a significant increase in hindpay withdrawal latency^[3,5].Intrathecal administration of CGRP 8-37 (human) can reversed the SP-induced decrease in latency to both withdrawal responses ,besides,it can mediated a significant increase in response latency ^[6].When performed to investigate the effects of intrathecal administration of CGRP 8-37 (human) on the HWL and HWT in rats with unilateral hindpaw inflammation induced by subcutaneous injection of carrageenin.Intrathecal administration of 10 nmol of CGRP8-37 induced a significant bilateral increase in the HWL and HWT in rats with experimentally induced inflammation^[4]. CGRP 8-37 (human) could enhance ALI induced by LPS in the rat model, and regulate the expression levels of AQP-1 and AQP-5 by affecting inflammatory cytokines^[7]. CGRP8-37 and Endomorphin-1 alone, and in combinated administration, as bolus and continues dose.Endomorphin-1and CGRP 8-37 (human) injections were able to reduce neuropathic pain after spinal cord compression injury^[8]. The presence of calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) was investigated. CGRP and its receptor antagonists, olcegepant and CGRP 8-37 (human), were microinjected into the vlPAG while changes of neural responses in the trigeminocervical complex (TCC) were monitored. Inhibition of TCC responses to stimulation of dural afferents and ophthalmic cutaneous receptive fields after microinjection of bicuculline into vlPAG indicated a connection between the vlPAG and TCC neurons. CGRP facilitated these TCC responses, whereas olcegepant and CGRP 8-37 (human) decreased them^[9].

References:
[1]. Luo HM, Wu X, et,al. Calcitonin gene-related peptide inhibits angiotensin II-induced NADPH oxidase-dependent ROS via the Src/STAT3 signalling pathway. J Cell Mol Med. 2020 Jun;24(11):6426-6437. doi: 10.1111/jcmm.15288. Epub 2020 May 5. PMID: 32372557; PMCID: PMC7294141.
[2]. Bennett AD, Chastain KM, Hulsebosch CE. Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain. Pain. 2000 May;86(1-2):163-75. doi: 10.1016/s0304-3959(00)00242-6. PMID: 10779673.
[3]. Yu LC, Hansson P, et,al. The calcitonin gene-related peptide antagonist CGRP8-37 increases the latency to withdrawal responses in rats. Brain Res. 1994 Aug 8;653(1-2):223-30. doi: 10.1016/0006-8993(94)90393-x. Erratum in: Brain Res 1994 Dec 15;666(2):295. PMID: 7526959.
[4]. Yu LC, Hansson P, et,al. Intrathecal CGRP8-37-induced bilateral increase in hindpaw withdrawal latency in rats with unilateral inflammation. Br J Pharmacol. 1996 Jan;117(1):43-50. doi: 10.1111/j.1476-5381.1996.tb15152.x. PMID: 8825341; PMCID: PMC1909388.
[5]. LÖfgren O, Yu LC, et,al. Intrathecal CGRP(8-37) results in a bilateral increase in hindpaw withdrawal latency in rats with a unilateral thermal injury. Neuropeptides. 1997 Dec;31(6):601-7. doi: 10.1016/s0143-4179(97)90006-8. PMID: 9574827.
[6]. Yu LC, Hansson P, et,al. Opioid antagonists naloxone, beta-funaltrexamine and naltrindole, but not nor-binaltorphimine, reverse the increased hindpaw withdrawal latency in rats induced by intrathecal administration of the calcitonin gene-related peptide antagonist CGRP8-37. Brain Res. 1995 Nov 6;698(1-2):23-9. doi: 10.1016/0006-8993(95)00752-c. PMID: 8581488.
[7]. Hong-Min F, Chun-Rong H, et,al.CGRP 8-37 enhances lipopolysaccharide-induced acute lung injury and regulating aquaporin 1 and 5 expressions in rats. J Physiol Biochem. 2016 Aug;73(3):381-386. doi: 10.1007/s13105-017-0563-3. Epub 2017 May 4. Erratum in: J Physiol Biochem. 2017 Oct 5;: PMID: 28470555.
[8]. Janzadeh A, Karami Z, et,al.The role of CGRP receptor antagonist (CGRP8-37) and Endomorphin-1 combination therapy on neuropathic pain alleviation and expression of Sigma-1 receptors and antioxidants in rats. J Chem Neuroanat. 2020 Jul;106:101771. doi: 10.1016/j.jchemneu.2020.101771. Epub 2020 Feb 21. PMID: 32092447.
[9].Pozo-Rosich P, Storer RJ, et,al. Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia. 2015 Dec;35(14):1298-307. doi: 10.1177/0333102415576723. Epub 2015 Mar 19. PMID: 25792688.

Cas No.	119911-68-1	SDF
Canonical SMILES	CC(C[C@@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](N)([H])C(C)C)([H])[C@@](O)([H])C)([H])CC1=CN=CN1)([H])CCCNC(N)=N)([H])CC(C)C)([H])C)([H])/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/C/C(O
Formula	C₁₃₉H₂₃₀N₄₄O₃₈	M.Wt	3125.59
Solubility	Soluble to 0.50 mg/ml in sterile water	Storage	Desiccate at -20°C
General tips	Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition	Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
		1 mg	5 mg	10 mg
	1 mM	0.3199 mL	1.5997 mL	3.1994 mL
	5 mM	0.064 mL	0.3199 mL	0.6399 mL
	10 mM	0.032 mL	0.16 mL	0.3199 mL

Molarity Calculator
Dilution Calculator

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal:μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Related Products

Reviews

Review for CGRP 8-37 (human)

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star

100%

4 Star

0%

3 Star

0%

2 Star

0%

1 Star

0%

Review for CGRP 8-37 (human)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

Overall Rating

★

Review Title

Review

Nickname

Email

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

CGRP 8-37 (human)

Customer Reviews

GlpBio Citations

Bioactive Compounds Premium Provider